Lymphoma, Large B-Cell, Diffuse clinical trials
The registry lists 1,390 studies for Lymphoma, Large B-Cell, Diffuse across more than 10 countries. 352 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-09-25.
Status
- Completed
- 523
- Recruiting
- 267
- Terminated
- 185
- Status unknown
- 147
- Active, not recruiting
- 127
- Not yet recruiting
- 75
Phase
- Phase 2
- 707
- Phase 1
- 497
- Phase 3
- 132
- Early Phase 1
- 18
- Phase 4
- 10
Where
- United States
- 711
- China
- 320
- Italy
- 162
- France
- 157
- Spain
- 123
- United Kingdom
- 112
Who runs them
National Cancer Institute (NCI) (102) · Fred Hutchinson Cancer Center (43) · Ruijin Hospital (36) · Hoffmann-La Roche (33) · Novartis Pharmaceuticals (25) · City of Hope Medical Center (23) · Sun Yat-sen University (19) · Fondazione Italiana Linfomi - ETS (18)
Studies
Recruiting first, then most recently updated. Showing 50 of 1,390 — search for more.
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaRecruitingNCT06091865Phase 321 countries
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingNCT05139017Phase 2/326 countries
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingNCT06890884Phase 29 countries
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingNCT06717347Phase 335 countries
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)RecruitingNCT07519772Phase 1/214 countries
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingNCT06649812Phase 21 country
- Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T TreatmentRecruitingNCT067841671 country
- Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell LymphomaRecruitingNCT06220032Phase 31 country
- Leukapheresis for CAR or Adoptive Cell Therapy ManufacturingEnrolling by invitationNCT032267041 country
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingNCT03223610Phase 1/21 country
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )RecruitingNCT07101328Phase 112 countries
- A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersRecruitingNCT07226843Phase 18 countries
- Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)RecruitingNCT06395103Phase 1/223 countries
- Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingNCT05757219Phase 21 country
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingNCT04002947Phase 21 country
- Study of Out of Specification for TisagenlecleucelRecruitingNCT04094311Phase 32 countries
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT07195916Phase 15 countries
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 11 country
- Proton Therapy for Mediastinal Lymphoma (PROMLY)RecruitingNCT07817641Not applicable1 country
- A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaNot yet recruitingNCT07818499Phase 1/21 country
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/216 countries
- Lifestyles Implemented-Survivorship Care Plan In Lymphoma SurvivorsRecruitingNCT05934084Not applicable1 country
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingNCT06806033Phase 27 countries
- Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingNCT07814001Phase 21 country
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell LymphomaRecruitingNCT05272384Phase 11 country
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07808827Phase 31 country
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 11 country
- An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell LymphomaRecruitingNCT072003752 countries
- Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell LymphomasNot yet recruitingNCT078041731 country
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingNCT05952024Phase 25 countries
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 21 country
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingNCT06500273Phase 24 countries
- Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TRecruitingNCT06784726Phase 21 country
- CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell TransplantRecruitingNCT06687772Phase 21 country
- Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT07284433Phase 1/22 countries
- Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07365306Phase 21 country
- A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell MalignanciesRecruitingNCT05836896Phase 11 country
- Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ MalignanciesRecruitingNCT06227026Phase 11 country
- A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 16 countries
- A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaRecruitingNCT07788118Phase 1/21 country
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaRecruitingNCT05826535Phase 1/22 countries
- Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell LymphomaRecruitingNCT06594939Phase 21 country
- Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated LymphomasRecruitingNCT05389423Phase 11 country
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT06536049Phase 1/21 country
- Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaNot yet recruitingNCT07588698Phase 21 country
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruitingNCT04104776Phase 1/27 countries
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 21 country
- Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06792253Phase 31 country
- A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesNot yet recruitingNCT07735533Phase 1/2
- R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS LymphomaNot yet recruitingNCT07764601Not applicable1 country